Why the study?
The optimal anticoagulant for stroke prophylaxis in end-stage renal disease is unknown, warfarin efficacy and safety remain debatable, and real-world evidence for direct oral anticoagulants in this population is limited.
Does rivaroxaban reduce thromboembolism and bleeding in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation compared with warfarin?
Does rivaroxaban reduce thromboembolism and bleeding in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation compared with warfarin?
In Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation, rivaroxaban was associated with a lower risk of thromboembolism and a similar risk of major bleeding compared with warfarin.
No takes yet. Share an insight, caveat, or question.
Rivaroxaban was associated with lower thromboembolism risk and similar major bleeding versus warfarin in ESRD with NVAF; leaves open confirmation in randomized trials.
Lin et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: